Authors: Caterina Fumagalli, Giovanni Serio
Categories: Review, indeterminate nodules, molecular testing, thyroid
Source: Pathologica
Thyroid nodules are commonly encountered in clinical practice, affecting up to 50% of the population. The large majority of thyroid lumps are benign incidental findings detected by imaging, while approximately 5-15% harbor malignancy. For a target patient’s care, it is of paramount importance to identify and treat thyroid malignancy, while preventing unnecessary invasive surgery in patients with benign lesions. Although fine needle aspiration (FNA) associated with cytological examination provides malignant risk information, 20-30% of diagnoses fall into the “indeterminate thyroid nodule” (ITN) category. ITN clinical management remains a challenging issue for physicians since the ITN risk of malignancy varies from 5% to 40% and most thyroid nodules undergo overtreatment with surgery procedures. ITN molecular testing may better define malignant risk in the single nodule and is able to discriminate with accuracy benign from malignant nodules. Nowadays there are different technologies and different molecular panels, each with its own specificity, sensitivity and predictive values. In view of widespread introduction of molecular testing, some outstanding questions remain and are addressed in the present review such as the presence of molecular panels acting as “rule in” or “rule out” tools, the effective impact of testing results in the clinical decision-making process, and the prohibitive cost of commercial assays associated with the lack of test reimbursement in national health systems.
**Key ** thyroid, indeterminate nodules, molecular testing
Thyroid carcinoma accounts for more than 13,000 new cancer diagnoses in Italy, with a predominance of women affected, and represents the second most common malignancy in females under 40 years old ^1^. The incidence of thyroid tumors has been increasing over the past decades, partly owning to incidentally detected non-palpable small nodules by imaging. Thyroid nodules are very common and their prevalence may involve 20-50% of the general population but only 5-15% of these nodules harbor malignancy ^2,3^. Even if the American ^4^ and Italian ^5^ guidelines definitively support a conservative surgery approach since low-risk thyroid nodules can be safely monitored, most thyroid nodules undergo over-diagnosis and over-treatment in routine daily practice ^6^. To date, an accurate identification of the subgroup of clinically relevant nodules is the goal to be achieved to avoid unnecessary invasive procedures in patients with benign and asymptomatic lesions.
In this setting, fine needle aspiration (FNA) cytology provides accurate diagnostic information to evaluate thyroid nodules ^7^. FNA is a rapid, cost effective and reliable tool that can be performed as an outpatient procedure with a complication rate that is very low. Different systems for reporting thyroid cytopathology may be applied, with different diagnostic categories and risk of malignancy. The Bethesda System includes six categories to classify thyroid nodules, and specifically category I is defined as nondiagnostic or insufficient, category II benign, category III includes “atypia of undetermined significance” (AUS) and “follicular lesion of undetermined significance” (FLUS), category IV represents “follicular neoplasm/suspicious for follicular neoplasm” (FN/SFN) while categories 5 and 6 are suspicious for malignancy and malignant, respectively ^8^. The Italian consensus guidelines reported a classification encompassing TIR 1 non-diagnostic, TIR 1C cystic, TIR 2 negative for malignant cells/benign, TIR 3A low-risk indeterminate lesion, TIR 3B high-risk indeterminate lesion, TIR 4 suspicious of malignancy, and TIR 5 positive for malignant cells ^5^. The Royal College of Pathologist (RCP) thyroid cytology reporting system includes Thy1 non-diagnostic for cytological diagnosis, Thy1c non-diagnostic cystic lesion, Thy2 non-neoplastic, Thy2c non-neoplastic cystic lesion, Thy3a neoplasm possible-atypia/ non-diagnostic, Thy3f neoplasm possible, suggesting follicular neoplasm, Thy4 suspicious of malignancy, and Thy5 malignant ^9^. The comparison among the three classification systems is reported in Table I.
Cytological examination has an excellent accuracy in discriminating between benign and malignant nodules, with a negative predictive value of Bethesda class II of 97% and a positive predictive value of 75% for Bethesda category V and up to 99% for Bethesda category VI ^8,10^. However the indeterminate thyroid nodule (ITN) category (Fig. 1) defined as Bethesda class III (BIII) and IV (BIV), RCP Thy3a and Thy3f and Italian TIR 3A and TIR 3B counts for 20-30% of all thyroid nodules and commonly requires further evaluations, having a risk of malignancy of 5-25% (BIII, TIR 3A, Thy3a) and 25-40% (BIV, TIR 3B, Thy3f), respectively ^5,9,11^.
Figure 1. Cytological features of the indeterminate thyroid nodules (A) Specimen obscured by blood that does not allow an evaluation of cellular details; (B) Few atypical cells; (C) Architectural atypia in poorly cellular specimen; (D) Specimen where sparse colloid is evident and where a definite distinction between a follicular neoplasm and a hyperplastic nodule is difficult; (E) Micro- and macro-follicular pattern; (F) Diffuse and monotonous architectural atypia suggesting follicular neoplasm.
An important step to better define the risk of malignancy in ITN has been made by the identification of specific gene alterations that are most frequently associated to thyroid malignant behaviour. In this review, we report on the development of different molecular assays, investigating various targets with particular technologies. We also assess the added benefit in clinical management of ITN by coupling molecular testing to FNA cytology along with the critical issue of the high cost for a widespread testing implementation.
The molecular pathogenesis of thyroid carcinomas mainly involves dysregulation of different pathways that control cellular proliferation and differentiation, in particular the mitogen activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/AKT signalling are the most affected (Fig. 2). The altered genes and the frequency of mutation vary among different histotypes ^12^. A mutation in the BRAF gene (mostly V600E) is found in up to 60% of papillary thyroid cancers (PTC) ^13^, 45% of anaplastic thyroid cancers (ATC) ^14^ and 33% of poorly differentiated thyroid cancers (PDTC) ^15^. Mutations in RAS gene family, including HRAS, KRAS and NRAS genes, affect follicular thyroid carcinomas (FTC) (about 50% NRAS mut) ^16^, PTC (6% NRAS mut) ^13^, PDTC (20% NRAS mut) ^15^ but also benign follicular adenomas (20-40%) ^17^ as well as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) (30%) ^18^. Other common alterations include RET-PTC fusions, mainly found in PDTC or radiation-related PTC, and PAX8-PPARG rearrangement observed in FTC (30-50%), the follicular variant of papillary thyroid cancer (38%) but also in follicular adenomas (2-13%) ^2,19,20^. PIK3CA mutations mark predominantly ATC, as found altered in up to 20% of ATC ^21^. Moreover, p53 and Wnt/Beta catenin signalling may be altered in PDTC and ATC, associated with progression, malignant behavior and dedifferentiation. PDTC and ATC frequently harbour mutation in TERT promoter region (up to 40% PDTC and up to 70% ATC) ^14,21^. Conversely, TP53 and TERT mutations are reported in less than 10% and 1% of PTC, respectively ^22^.
Figure 2. Pathways commonly affected in thyroid carcinoma. The most frequent alterations are depicted. GF: growth factor; RTK: receptor tyrosine kinase.
Molecular testing of FNA specimens is a potentially practice-changing approach to better define ITN. The American Thyroid Association (ATA) ^23^, the NCCN ^24^, the American Association of Clinical Endocrinologists (AACE), American College of Endocrinology, and Associazione Medici Endocrinologi ^25^ and the Italian AIOM (Associazione Italiana Oncologia Medica) ^26^ guidelines suggest that molecular testing may be considered when assessing the risk of malignancy of ITN, most notably when molecular results would influence the choice of surgery. A critical issue is which molecular test to perform. About this, The American Association of Endocrine Surgeons ‘To be useful for deciding extent of surgery, a given molecular test needs to first provide reliable prognostic information’ ^27^. Given that a benign cytologic diagnosis on a thyroid FNA is expected to rule out malignancy in 97% of cases, and the positive predictive value of a FNA malignant result reaches 98%, a reliable molecular test ought to perform with similar accuracy to discriminate between benign and malignant nodules.
To evaluate the accuracy of a diagnostic test, sensitivity (SN), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) are all parameters to take into account. To note, according to Bayes’ theorem the disease prevalence influences the predictive values as PPV decrease if decreases prevalence decreases and NPV decreases if the prevalence increases and vice versa. Diagnostic test with a high SN and high NPV are considered valid to “rule out” the presence of disease, whereas a diagnostic test with high SP and PPV are good to “rule in” disease, suggesting that a positive result is consistent with malignancy. An ideal test should accurately discriminate between benign and malignant disease and consequently have a high sensitivity and high specificity ^28^.
In 2009-2010, the first molecular testing performed on ITN included the evaluation of point mutation in BRAF, KRAS, NRAS, HRAS genes and the rearrangements RET/PTC1, RET/PTC3 and PAX8/PPARG ^29-31^. This 7-gene panel applied to thyroid FNA samples with indeterminate cytology is considered as a valid “rule in” test, given the high specificity (SP of 99% and 97% for BIII and BIV nodules, respectively) and positive predictive value (PPV of 88% and 87% for BIII and BIV nodules, respectively). However, the low diagnostic test sensitivity (SN of 63% and 57% for BIII and BIV nodules, respectively) and negative predictive value (NPV of 94% and 86% for BIII and BIV nodules, respectively) show that not all malignancies carry variants or fusions detected by this panel ^32^. Of note, the malignancy predictive value of molecular alterations varies according to the gene affected and the specific variant or fusion detected. As reported in the systematic review performed by Gordner and colleagues ^33^, the BRAF^V600E^ mutation alone has the highest positive predictive value (PPV) amounting to 98%, whereas other common alterations have lower PPV, such as the fusion PAX8/PPARG (55%), HRAS^Q61R^ (45%), BRAF^K601E^ (42%), and NRAS^Q61R^ (38%). The PPV increases when multiple alterations are found in the same nodule, achieving a cumulative PPV of 77%. On the other hand, about 60% of all ITN harbor a RAS mutation that is mostly associated with benign or low-risk tumors ^4^. In addition, different studies have reported on molecular alterations in benign lesions, with a frequency ranging from 0% to 48% for RAS mutations, from 0% to 68% for RET/PTC rearrangements and from 0% to 55% for PAX8/PPAR-gamma rearrangements ^34^.
In 2012, the Afirma Gene Expression Classifier (GEC) (Veracyte, San Francisco, CA) was designed as a “rule out” molecular tool. The GEC panel evaluates the expression of 167 genes using microarrays, with a negative predictive value of the “benign” category reaching 95% ^35,36^. The validation study ^35^ involved 265 ITN nodules and was 92% and 52% in overall SN and SP, respectively. The NPV associated with a GEC benign result was 95% and 94% for BIII and BIV nodules, respectively.
Later, several molecular tests investigating both DNA and RNA or miRNA were developed, aiming to perform as both “rule in” and “rule out” tests. In 2013 the ThyroSeq panel v1 (Sonic Healthcare, Rye Brook, NY) is a DNA-based NGS assay that investigates 12-genes for point mutations, namely AKT1, BRAF, NRAS, KRAS, HRAS, PTEN, TP53, TSHR, GNAS, CTNNB1, RET, PIK3CA ^37^. In 2014 the enriched version ThyroSeq v.2 coupled the DNA-based with the RNA-based NGS, testing simultaneously for point mutations in 13 genes (added TERT gene promoter region) and for 42 types of gene fusions occurring in thyroid cancer ^38^. The ThyroSeq assay has been additionally expanded in 2015, ThyroSeq v.2.1, with the introduction of EIF1AX gene evaluation, investigating 14 genes for point mutations along with 42 gene fusions, reaching the following SN 90.9%, SP 92.1%, PPV 76.9%, and NPV 97.2% for ITN nodules at cancer prevalence of 22.5% ^39^.
In 2015 the multiplatform mutation and miRNA test (MPT) was introduced. The ThyGenX/ThyraMIR (Interpace Diagnostics, Parsippany, NJ) combines an 8-gene panel (ThyGenX) with a 10-microRNA (miRNA) expression panel (ThyraMIR) ^40^. The ThyGenX expands the original 7-gene panel with the analysis of PIK3CA gene, mostly altered in FTC and PCTC. The ThyraMIR panel evaluates the expression of 10 mi-RNA, short (~21-23 nucleotides long) non-coding RNAs that negatively modulate the expression of target genes by degradating mRNAs or translational silencing. The ThyraMIR panel subsequently performed tafter a negative result with the 7-gene panel, allows to reach a SN of 89%, SP of 85%, 74% PPV and 94% NPV for BIII and BIV nodules with cancer prevalence of 32% ^40^. Another assay investigating miRNA is the Rosetta GX Reveal assay (Rosetta Genomics Ltd, Rehovot, Israel) that can be performed on a single FNA smear, stained with Papanicolaou or Romanowsky-type stains (Diff-Quik and May Grünwald Giemsa) for cytologic evaluation and stored at room temperature. The assay measures 24 miRNAs to classify cytologically ITNs into benign, suspicious for malignancy, or positive for medullary carcinoma. The assay can be run on smears represented by 1% of thyroid epithelial cells or from which at least 5 ng of RNA have been extracted ^41^. The multicenter validation study reported a NPV of 91%, SN of 85% and SP of 72% increased to 99%, 98% and 78%, respectively, evaluating only cases in which all three reviewing pathologists reached an agreement on the diagnosis ^42^.
Nowadays the most commonly used preoperative molecular tests are Afirma (Veracyte, San Francisco, CA), ThyroSeq (Sonic Healthcare, Rye Brook, NY) and the Multiplatform Test Approach (MPT) (Interpace Diagnostics, Parsippany, NJ), with the most updated version of Afirma Genomic Sequencing Classifier (GSC), Thyroseq v3 and MPTX v2, all centrally performed.
The ThyroSeq v3 Genomic Classifier (GC) is a targeted next-generation sequencing test that analyzes DNA/RNA of 112 thyroid cancer-related genes for point mutations, insertions/deletions, gene fusions, copy number alterations, or gene expression alterations ^43^. A GC score is calculated according to the genetic alteration detected. Each alteration has an assigned value based on the strength of association with 0 (no association with cancer), 1 (low cancer probability), or 2 (high cancer probability). A multicenter study evaluating the performance of Thyroseq v.3 reported in Bethesda III and IV nodules 94% SN, 82% SP, 97% NPV and 66% PPV at 28% cancer/NIPT prevalence ^44^.
The most widely used sample type for Thyroseq assay is FNA material collected directly into a tube with nucleic acid preservative solution at the time of the FNA procedure. However, a recent study validated slide scraping on cytology smears as an alternative source for ThyroSeq analysis in indeterminate thyroid nodules ^45^.
The Afirma GSC is a RNA-based NGS panel in which whole transcriptome analysis is combined with machine learning algorithms to provide a benign or suspicious result in nodules with ITN. In the validation study ^46^, the AFIRMA GSC panel showed a SN of 91%, SP of 68%, PPV of 47%, and NPV of 96%. The real world implementation of Afirma GSC testing is depicted in the meta-analysis of Nasr and colleagues ^47^, including 13-independent studies, with a pooled data of 97% of SN and 99% of NPV. Moreover, in this meta-analysis are elaborated the observed SP (oSP) and observed PPV (oPPV), excluding from the analysis unoperated patients with suspicious results, and the conservative SP (cSP) and conservative (cPPV), assuming as histology negatives unoperated patients with suspicious results. The corresponding values obtained were 88% and 65% for oSP and oPPV, respectively, and 80% and 49% for cSP and cPPV, respectively.
Of note, the starting material used for the Afirma molecular analyses is exclusively FNA sample collected and shipped at specific conditions, according to the Veracyte Afirma Genomic Testing specimen’s collection instructions.
The MPTX v.1 assay is an expanded NGS test (ThyGeNEXT) used in combination with the microRNA risk classifier test (ThyraMIR) ^48^. The expanded ThyGeNEXT mutation panel includes NTRK and ALK fusions as well as TERT and RET mutations. In MPTX testing, cases with no detectable mutations or with weak driver mutations are further risk stratified using the microRNA classifier, which incorporates two thresholds for malignancy risk. MPTX results are reported as one of three categories (negative, moderate, or positive) based on results of the mutation panel and microRNA risk classifier thresholds. In the multicenter study by Lupo and colleagues ^49^ on ITN, the MPTX v.1 had 95% SN, 90% SP, 97% NPV and 75% PPV, at 30% disease prevalence. In the last study, using the MPTX v.2 integrated with the pairwise miRNA expression analysis, the diagnostic accuracy of ITN risk stratification improved, reporting a SN of 98% ^50^.
The MPTX can be successfully performed on FNA specimens either in RNA preservative fluid or on cytology slides, as recently demonstrated by Kumar ^51^. The comparison between molecular results of FNA specimens in RNA preservative and matched FNA cytology smears from 47 patients demonstrated 98% concordance between the results of NGS-based mutation sequencing tests and 90% concordance between the results of microRNA expression-based tests.
According to the most recent meta-analysis by Lee and colleagues in 2022 ^52^ comparing the performances of Afirma GCS (Genomic Sequencing Classifier) and ThyorSeq v.3 panels on Bethesda III or IV cases, and no statistically differences were observed. No comparison has been performed with MPTX, due to the small sample size examined with this test. Pooled data obtained by 7 studies including 472 patients and 6 studies enrolling 530 patients, evaluating with Afirma GCS (A) and Thyroseq v.3 (T) assays respectively, showed similar performance in terms of SN (A:97%, T:95%), SP (A:53%; T:50%), PPV (A:63%, T:70%) and NPV (A:96%, T:92%).
The introduction of molecular testing in the management of thyroid nodules with indeterminate cytology may significantly decreases the number of surgical procedures carried out (up to 39-68%) ^53-60^.
In the study of Jug and colleagues ^55^ the majority of patients with a suspicious Afirma GEC result proceeded to surgical resection (81% underwent surgery) whereas only 13% of patients with a benign result underwent surgery. Samulski ^56^ reported that 107/136 (79%) of suspicious nodules and 23/158 (15%) of benign or quantity insufficient nodules underwent surgical resection. Moreover, adopting the Afirma GSC instead of GEC panel, the rate of surgical intervention in the indeterminate nodule cohort further decreased, mainly due to the improvement in the Benign Call Rate (BCR). According to the meta-analysis of Vuong and colleagues ^57^, the implementation of GSC panel resulted in an approximately 50% relative reduction of surgical interventions and a significant increase of the BCR from the 43.8% of GEC to 65.3% of the GSC. As reported by Endo and colleagues ^54^, the reduction in surgical procedures was statistically significant in both nodules with Bethesda III and Bethesda IV diagnoses. Switching from GEC to GSC they reported that the surgical rate decreased from 51.3% to 14.9% and from 54.8% to 33.3% in Bethesda III and Bethesda IV nodules, respectively.
In the study of Jug ^55^, the identification of “high risk mutations” applying the ThyroSeq panel was associated to subsequent surgery in 85% of patients, whereas 44% of patients without high-risk mutations underwent surgery. At the same, in the series described by Valderrabano and collegues ^58^, 33/45 (71%) of “high-risk mutations” nodules and 64/137 (47%) of “no high-risk mutations” nodules were surgically resected. In the experience reported by Desai ^59^, 96/121 (79%) Thyroseq positive and only 31/294 (11%) Thyroseq negative nodules underwent surgery.
The randomized controlled trial reported by Livhits ^60^, confirmed that the Afirma GSC and Thyroseqv3 have similar specificity and potential to reduce diagnostic surgery of ITN. In detail, 346 patients with ITN were evaluated either with the Afirma GSC (A) or ThyroSeq v3 (T) panel, according to a monthly block randomization scheme. The prevalence of malignancy was 20% among indeterminate nodules. No significant differences were observed adopting one or the other molecular assay in terms of benign call rate (A: 53%, T: 61%), SP (A: 80% and T:85%) and PPV (A: 53% and T:63%). Diagnostic thyroid surgery was avoided in 87 (51%) patients tested with the Afirma GSC panel and in 83 (49%) patients tested with the ThyroSeq v3 test.
In many European countries and in Italy in particular, there is no reimbursement for ITN molecular testing, even if reducing the number of unnecessary diagnostic thyroid surgeries has huge implications for patient quality of life and costs of health care. Notably, the commercially available tests mentioned above require high-throughput technologies and skilled personnel to be performed. They are run in company laboratories and cost about 6400 per test, depending on the specific assay ^61,62^. Because of the prohibitive assay cost, they are rarely requested in the Italian routine clinical setting. Given the established clinical utility of ITN molecular testing, different strategies may be adopted to overcome this
The impact of ^18^F-fluorodeoxyglucose (FDG) PET/CT imaging in ITN risk classification and subsequent surgery sparing has been recently investigated in a multicenter trial enrolling 132 patients with scheduled diagnostic surgery for an ITN nodule ^73^. The patients were randomized to diagnostic surgery or ^18^F-FDG PET/CT, undergoing surgery if ^18^F-FDG-positive. The study results showed that 83% of patients in the first group and 42% in the second group (p-value < 0.001) had undergone futile surgery. In particular, for non-Hürthle cell nodules applying ^18^F-FDG PET/CT can reduce unnecessary surgery by 48%. The ^18^F-FDG driven diagnostic workup had high SN and NPV, 94.1% and 95.1% respectively, with low SP and PPV resulting in a BCR of 31.1%.
Moreover, ^18^F-FDG PET/CT imaging produce quantitative parameters as SUVmax, SUVpeak, SUVmax-ratio, and SUVpeak-ratio, that can provide information to rule out malignancy in ITN ^74^. Indeed, quantitative ^18^F-FDG PET/CT assessment can differentiate preoperative ITN properties since a higher median value for conventional parameters was present in malignant/borderline nodules compared to benign nodules (p < 0.001). Considering that Hürthle cell nodules have a higher FDG avidity resulting in a higher SUV value even if they are benign nodules, higher SUV cut-offs should be applied in Hürthle cell nodules to optimize rule-out ability.
In the last years, radiomics defined as the high-throughput mining of quantitative image features from standard-of-care medical imaging has been investigated as additional tool for identifying malignancies, predicting prognosis or genomic mutation status in different tumors ^75,76^. PET/CT imaging can be the source of radiomic features (RFs) reported as histogram-based features, texture-based features, edge features, and shape features. In the study by de Koster and colleagues ^74^ radiomic analysis did not improve the discriminating power of ^18^F-FDG-PET/ CT in ruling out malignancy among ITN compared to ^18^F-FDG-PET/ CT visual evaluation or its quantitative analysis. However, in the retrospective study by Giovannella and colleagues ^77^ two RFs, shape_Sphericity and glcm_Autocorrelation, showed a significant ability to predict ITN malignancy (AUC = 0.733). These two RFs associated with cytological diagnosis (Bethesda classes) were integrated into a multiparametric model that increases the accuracy of risk stratification compared to Bethesda classification and PET/CT alone. In particular, considering the non-Hürthle cell nodule group, a high diagnostic accuracy was reached with a NPV of 95% and a PPV of 79%. Future studies are needed, possibly investigating non-Hurtle cell nodules and Hürthle cell nodules separately to identify RFs and to integrate quantitative parameters in the predictive model.
In the recent meta-analysis by Ko and colleagues ^78^, the use of ^18^F-FDG PET/CT-based RFs applied to thyroid incidentaloma was investigated. The authors included 5 studies, with differences in terms of RFs extraction and selection methods, types and number of features, and modelling methods. They reported a good diagnostic performance of ^18^F-FDG PET/CT-based RFs for prediction of malignant thyroid nodules, with a pooled SN and SP values of 0.77 and 0.67, respectively, but they could not recommend the proper radiomics feature selection method or radiomics model method.
These promising results could lead to an expanded use of PET/CT imaging as an additional tool in defining ITN malignant risk.
Liquid biopsy has been emerged as a minimally invasive tool to support diagnosis, refining risk stratification, complementing follow-up, and improving treatment of cancer patients. In the last years, the DNA released by the cell in the blood-stream, the cell-free DNA (cfDNA) and in particular the amount of DNA released by the cancer cells namely circulating tumor DNA (ctDNA), has been evaluated as a surrogate for tumor tissue DNA. In the ITN setting, the potential role of liquid biopsy to discriminate between benign and malignant nodules has been explored. In particular, the most frequently investigated biomarker is BRAF^V600E^ in cfDNA that correlates with a diagnosis of PTC ^79-81^. Other specific biomarkers may be useful in discriminating between PTC and benign nodules including epigenetic traits such as the methylation status of RASSF1 and SLC5A8 ^81^ of MGMT ^82^ or CALCA, CDH1, TIMP3, DAPK, and RARB2 genes ^83^ or serum expression levels of miRNA-95 and -190 ^84^. On the other hand, there are non-specific biomarkers evaluated for refining the diagnosis of indeterminate thyroid nodule such as the quantification of cfDNA or cfDNA fragmentation index ^85,86^. In the recent meta-analysis by Hou ^87^ and colleagues all these biomarkers were debated. They found that a combination of multiple cfDNA biomarkers may be more accurate than single biomarker testing. Individually comparing cfDNA mutations, cfDNA methylation, cfDNA integrity index and quantitative analysis (cfDNA level) as potential biomarkers, they reported a high diagnostic accuracy of TC for cfDNA levels, with a sensitivity of 0.84 (0.67-0.94) and specificity of 0.89 (0.85-0.92), even if large-scale studies are needed to ascertain its diagnostic utility. To date, the role of liquid biopsy in complementing an indeterminate thyroid cytology diagnosis remains to be established in a routine clinical setting.
In the clinical setting of patients with thyroid nodules, the challenging issue consists in the management of indeterminate nodules, accounting for 20-30% of nodules, whereas FNA cytological evaluation alone fails to distinguish between benign or malignant features. Coupling FNA cytological evaluation and molecular testing can improve targeted patient care and guide surgical decision making. The commercially available tests are affordable “rule in” and “rule out” tools. The costs of molecular testing and the sustainability in the public health system remains to be addressed beforewidespread clinical implementation.
The authors declare no conflict of interest.
None
None
CF and GS: manuscript conception, writing and reviewing.